3652 results for «383»
3652 results
Challenging TAVI access: exploring transfemoral boundaries and mastering alternative access
20 May 2026 – From EuroPCR 2026
This session investigates the boundaries of transfemoral access for TAVI and strategies to safely extend its use. It also provides a comprehensive review of facilitated transfemoral TAVI techniques and explores alternative access options, offering critical insights for managing challenging TAVI cases.
Multi-device approach to calcified lesions
20 May 2026 – From EuroPCR 2026
Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
TAVI for aortic regurgitation
20 May 2026 – From EuroPCR 2026
This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.
Lost, crushed, fractured: stent complications in real life
20 May 2026 – From EuroPCR 2026
This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.
Transcatheter rescue in cardiogenic shock
20 May 2026 – From EuroPCR 2026
This session presents cutting-edge transcatheter rescue interventions in cardiogenic shock scenarios. It covers emergent valve-in-valve procedures, hybrid approaches for valvular heart disease with heart failure, management of ventricular septal rupture post-myocardial infarction, and percutaneous closure techniques for high-risk patients, emphasizing lifesaving interventional strategies.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
Imaging guidance in everyday practice
20 May 2026 – From EuroPCR 2026
This session emphasizes the role of imaging guidance in everyday interventional cardiology practice. Through challenging cases involving exertional chest pain, unusual coronary anatomy, complex left ventricular access, side branch navigation, and IVUS-guided re-intervention, it underscores the critical value of advanced imaging for diagnostic clarity and procedural...
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)
08 Apr 2024
Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.
Author
The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction
18 Nov 2024
Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.
Author
NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation
01 Sep 2024
Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.
Author
Author
Author
